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Summary
Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if 
deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and 
efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.
Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, 
Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 
vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 
nCoV-19 group received two doses containing 5 × 10¹⁰ viral particles (standard dose; SD/SD cohort); a subset in the UK 
trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The 
primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid 
amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according 
to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 − relative risk derived from 
a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, 
NCT04324606, NCT04400838, and NCT04444674.
Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 
4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard 
doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs 71 [1·6%] 
of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy 
was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both 
groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, 
there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, 
including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 
175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control 
group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the 
control group, and one in a participant who remains masked to group allocation.
Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against 
symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
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Introduction
As the COVID-19 pandemic, caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), 
continues to unfold, there has been widespread impact 
on health, including substantial mortality among older 
adults and those with pre-existing health conditions,1,2 
and repercussions for the global economy, caused by 
physical distancing measures, with the greatest conse-
quences for the most vulnerable in society.
Despite global spread of the virus, a large proportion of 
the population in many countries is thought to have thus 
far escaped infection and remains non-immune to 
SARS-CoV-2.3 Vaccines could play an important role in 
increasing population immunity, preventing severe 
disease, and reducing the ongoing health crisis. In 
response, rapid global efforts to develop and test vaccines 
against SARS-CoV-2 have led to an unprecedented 
number of candidate vaccines starting clinical trials 
during 2020. Currently, 48 vaccines are under clinical 
evaluation.4 Several of these have shown good safety and 
immunogenicity, and 11 of these are currently being 
evaluated in phase 3 clinical efficacy studies.
The ChAdOx1 nCoV-19 vaccine (AZD1222) was 
developed at Oxford University and consists of a 
replication-deficient chimpanzee adenoviral vector 
ChAdOx1, containing the SARS-CoV-2 structural surface 
glycoprotein antigen (spike protein; nCoV-19) gene.
Following initiation of a phase 1 clinical trial in the UK 
(COV001) on April 23, 2020, three further randomised 
controlled trials of the candidate vaccine were initiated 
across the UK (COV002), Brazil (COV003), and South 
Africa (COV005). A further phase 1/2 trial has recently 
been initiated in Kenya and is not reported here. The 
immunogenicity results from the phase 1/2 UK study, 
COV001, in 1077 healthy adults aged 18–55 years,5 and a 
phase 2 cohort in COV002 in older adults (≥56 years)6 
have been published and show an acceptable safety profile 
for the vaccine with induction of binding and neutralising 
antibodies as well as generation of interferon-γ enzyme-
linked immunospot responses, with higher antibody titres 
after a second dose of vaccine.5–7
The phase 1 study (COV001) included an efficacy cohort 
and the phase 2 and 3 studies (COV002, COV003, and 
COV005) expanded enrolment to a wider population of 
participants with higher likelihood of exposure to the 
virus, such as health-care workers. Exclusion criteria were 
reduced for phase 3 trials, so that older adults and 
individuals with a range of comorbidities were also 
enrolled.
All studies have completed enrolment of their 
respective efficacy cohorts and are in the follow-up phase. 
Paediatric studies have not yet been initiated.
Here, we present the combined interim analysis of 




This interim analysis of the efficacy and safety of 
the ChAdOx1 nCoV-19 vaccine includes data from 
four ongoing blinded, randomised, controlled trials done 
across three countries: COV001 (phase 1/2; UK), COV002 
(phase 2/3; UK), COV003 (phase 3; Brazil), and COV005 
(phase 1/2; South Africa). The interim efficacy is 
being assessed by a prespecified global pooled analysis 
combining data from COV002 and COV003. The safety of 
the vaccine is being assessed using data from all 
four studies (appendix 1 pp 3–4). Three of the studies 
are single blind and one is double blind (COV005). 
Primary efficacy was assessed in participants who received 
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Research in context
Evidence before this study
We searched PubMed for research articles published from 
database inception until Nov 23, 2020, with no language 
restrictions, using the terms “SARS-CoV-2”, “vaccine”, “clinical 
trial”, and “efficacy”. There were no peer-reviewed publications 
available on efficacy of any severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) vaccines in development and, 
at the time of the search, there were no licensed vaccines 
against SARS-CoV-2. Three vaccine developers recently 
reported initial efficacy results from phase 3 trials in the media 
(Pfizer/BioNTech, Moderna, and the Gamaleya National 
Research Center). Pfizer/BioNTech and Moderna, both 
developing mRNA vaccines, have reported initial efficacy 
results of 95% in their primary analysis (Pfizer/BioNTech) and 
94·5% in an interim analysis (Moderna). We have previously 
published safety and immunogenicity results of ChAdOx1 
nCoV-19 (AZD1222) for different age groups in phase 1/2 and 
2/3 trials.
Added value of this study
We report on the first clinical efficacy results of ChAdOx1 
nCoV-19 in a pooled analysis of phase 2/3 trials in the UK and 
Brazil, and safety data from more than 20 000 participants 
enrolled across four clinical trials in the UK, Brazil, and 
South Africa. ChAdOx1 nCoV-19 has an acceptable safety 
profile and is efficacious against symptomatic COVID-19, 
with no hospital admissions or severe cases reported in the 
ChAdOx1 nCoV-19 arm. The vaccine can be stored and 
distributed at 2–8°C, making it particularly suitable for global 
distribution.
Implications of all the available evidence
The development of safe, effective, affordable, and deployable 
vaccines against COVID-19 remains paramount in solving the 
pandemic crisis and re-establishing normality. The positive 
results presented here support regulatory submissions for 
conditional or emergency use of ChAdOx1 nCoV-19.
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two doses of the vaccine. All four studies included 
participants who received two doses, with a booster dose 
incorporated into the three trials6 that were initially 
designed to assess a single-dose of ChAdOx1 nCoV-19 
compared with control (COV001, COV002, and COV003) 
after review of the antibody response data from COV001.
Despite minor differences across the studies, there is 
sufficient consistency to justify the proposal for pooled 
analysis of data, which will provide greater precision 
for both efficacy and safety outcomes than can be 
achieved in individual studies and provides a broader 
understanding of the use of the vaccine in different 
populations. Once the studies were underway, a statistical 
analysis plan for the global pooled analysis of these 
studies was developed before data lock on Nov 4, 2020, 
and analysis, and was finalised with extensive feedback 
from national and international regulators (including 
the Medicines and Healthcare Products Regulatory 
Agency [UK] and the European Medicines Agency [EU]), 
including justification for including groups receiving 
different vaccine doses in the analysis (see statistical 
analysis plan for further details; appendix 2 pp 2–73). All 
participants in the four trials provided written informed 
consent.
Details of amendments to the four trial protocols and 
the statistical analysis plan are included in appendix 2 
(pp 9, 178–182, 327–335, 438–441, 548–550).
Study design and participants
COV001 (UK)
COV001 is a continuing single-blind phase 1/2 clinical 
trial in five sites in the UK, which began on April 23, 2020, 
and enrolled 1077 healthy volunteers aged 18–55 years, as 
previously described.5 Briefly, healthy adult participants 
were enrolled after screening to exclude those with 
pre-existing health conditions. Participants were ran-
domly assigned 1:1 to receive ChAdOx1 nCoV-19 at a dose 
of 5 × 10¹⁰ viral particles (standard dose), mea sured using 
spectropho tometry, or meningococcal group A, C, W, 
and Y conjugate vaccine (MenACWY) as control. An 
open-label non-randomised subgroup of ten participants 
were given two doses of ChAdOx1 nCoV-19 28 days apart, 
as previously reported.5 This study was originally planned 
as a single-dose study and 88 participants in the phase 1 
part of the study remain recipients of a single dose. 
However, the protocol was modified to a two-dose regime, 
following an amendment on July 30, 2020 (version 9.0; 
appendix 2 pp 180–181), for the remaining phase 2 
cohorts as a result of robust booster responses identified 
in the evaluation of the early immunogenicity cohorts, 
with the booster dose given at the earliest possible time.5
COV002 (UK)
COV002 is a continuing single-blind phase 2/3 study 
in the UK that began on May 28, 2020, and enrolled 
participants in 19 study sites in England, Wales, and 
Scotland. Enrolment particularly targeted individuals 
working in profes sions with high possible exposure to 
SARS-CoV-2, such as health and social care settings.
Two dosage groups were included in COV002: 
participants who received a low dose of the vaccine 
(2·2 × 10¹⁰ viral particles) as their first dose and were 
boosted with a standard dose (in the LD/SD group), 
and subse quent cohorts who were vaccinated with 
two standard-dose vaccines (SD/SD group). Initial dosing 
in COV002 was with a batch manufactured at a contract 
manufacturing organisation using chromatographic 
purification. During quality control of this second batch, 
differences were observed between the quantification 
methods (spectrophotometry and quantitative PCR 
[qPCR]) prioritised by different manufacturing sites. In 
consultation with the national regulator (Medicines and 
Healthcare products Regulatory Agency), we selected 
a dose of 5 × 10¹⁰ viral particles by spectrophotometer 
(2·2 × 10¹⁰ viral particles by qPCR), in order to be 
consistent with the use of spectrophotometry in the 
phase 1 study (COV001),5 and to ensure the dose was 
within a safe and immunogenic range according to 
measurements by both methods. A lower-than-antici-
pated reactogenicity profile was noted in the trial, and 
unexpected interference of an excipient with the spec-
trophotometry assay was identified. After review and 
approval by the regulator, it was concluded that the qPCR 
(low-dose) reading was more accurate and further doses 
were adjusted to the standard dose (5 × 10¹⁰ viral particles) 
using a qPCR assay. The protocol was amended on 
June 5, 2020, resulting in enrolment of two distinct 
groups with different dosing regimens with no pause 
in enrolment (version 6.0; appendix 2 p 330). A suite of 
assays has now been developed for characterisation of 
concentration (which confirmed the low and standard 
dosing), and future batches are all released with a 
specification dose of 3·5–6·5 × 10¹⁰ viral particles, and 
this was used for the booster doses in the efficacy analysis 
presented here.
The LD/SD cohort (aged 18–55 years) was enrolled 
over 11 days between May 31 and June 10, 2020. The 
SD/SD cohort (aged 18–55 years) was enrolled from 
June 9 to July 20, 2020. Subsequently, enrolment of older 
age cohorts began (from Aug 8, 2020, for participants 
aged 56–69 years and from Aug 13, 2020, for partici-
pants aged ≥70 years), all of whom were assigned to 
two standard doses (SD/SD cohort). Each site imple-
mented the protocol amendment before changing 
from low-dose administration to standard-dose admin-
istration, and therefore there was no overlap in enrolment 
of participants in these cohorts.
The 18–55-year-old cohorts were originally planned as 
single-dose efficacy cohorts. However, the protocol was 
modified on July 20, 2020, to offer a second dose to 
the participants in these cohorts as a result of robust 
booster responses identified in the evaluation of the 
early immunogenicity cohorts (version 9.0; appendix 2 
pp 331–332).5 Boosting began on Aug 3, 2020, resulting 
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in a longer gap between prime and booster vaccines in 
these cohorts than for those aged 55–69 years and those 
aged 70 years or older, as these participants were enrolled 
into two-dose groups from the start.
Results for participants enrolled into immunogenicity 
subgroups have been previously published, including a 
small subset who received a low-dose boost.6 Full details 
are available in the study protocol (appendix 2 pp 184–342) 
and the procedures have been previously described.6
COV003 (Brazil)
COV003 is a continuing single-blind phase 3 study in 
Brazil that began on June 23, 2020. The focus of recruit-
ment was targeted at those at high risk of exposure to the 
virus, including health-care workers at six sites across 
Brazil. Participants were aged 18 years or older, and this 
trial included individuals with stable pre-existing health 
conditions. All participants were offered two doses of the 
vaccine at a dose of 3·5–6·5 × 10¹⁰ viral particles with 
administration up to 12 weeks apart (target 4 weeks), 
following a protocol amendment on July 28, 2020, to 
include booster groups (version 4.0; appendix 2 
pp 438–439). Full details are available in the study 
protocol (appendix 2 pp 343–441).
COV005 (South Africa)
COV005 is a continuing double-blind phase 1/2 study in 
South Africa in healthy adults aged 18–65 years living 
without HIV that began on June 28, 2020. An additional 
immunogenicity cohort of those living with HIV was also 
enrolled but are not included in this interim analysis. 
All participants were offered two doses of the vaccine at 
a dose of 3·5–6·5 × 10¹⁰ viral particles, with doses admin-
istered 4 weeks apart. A small subgroup of 44 participants 
received a half-dose vaccine (21 as their first dose and 
23 as their second dose) as a result of variability in the 
release assay, before the adoption of new methods for 
characterisation of concentration. Adjustment in dose 
was discussed with and approved by the national 
regulator. Full details are available in the study protocol 
(appendix 2 pp 442–559).
A combined independent data safety monitoring board 
reviews safety data from all four trials on a regular basis.
Randomisation and masking
In efficacy cohorts for all studies, participants were 
randomised 1:1 to receive ChAdOx1 nCoV-19 or a control 
product. In COV002, MenACWY was chosen as the 
control group vaccine to minimise the chance of acci-
dental participant unmasking due to local or systemic 
reactions to the vaccine. COV003 used MenACWY as the 
control for the first dose and saline for the second dose. In 
COV005, participants randomly assigned to the control 
group were administered saline solution. Randomisation 
lists were prepared by the study statistician (MV) using 
block randomisation, stratified by study site and study 
group, and uploaded into to the secure web platform 
used for the study electronic case report form (REDCap 
version 9.5.22) for COV001, COV002, and COV003. In 
COV005, the randomisation list was held by the unmasked 
study pharmacist who prepared the vaccines for admin-
istration, with all other trial staff masked to group 
allocation. The trial staff administering the vaccine pre-
pared vaccines out of sight of the par ticipants and syringes 
were covered with an opaque material until ready for 
administration to ensure masking of participants.
Procedures
The recombinant adenovirus for ChAdOx1 nCoV-19 was 
manufactured and vialed by Advent (Pomezia, Italy), and 
additional batches produced by COBRA Biologics (Keele, 
UK) and vialed by Symbiosis (Sterling, UK). Both were 
manufactured according to Good Manufacturing Practice 
and approved by the regulatory agency in the UK, the 
Medicines and Healthcare products Regulatory Agency.
Baseline assessments included review of inclusion 
and exclusion criteria, medical history, vital signs mea-
sure ment, history-directed clinical examination, and 
collection of serum for SARS-CoV-2 serology.
Participants across all four trials were asked to contact 
the study site if they experienced specific symptoms 
associated with COVID-19 and received regular 
reminders to do so. Those who met symp tomatic criteria 
had a clinical assessment, a swab taken for a nucleic acid 
amplification test (NAAT), and blood samples taken for 
safety and immunogenicity. In the UK and Brazil, the 
list of qualifying symptoms for swabbing included any 
one of the following: fever of at least 37·8°C, cough, 
shortness of breath, and anosmia or ageusia. In South 
Africa, the list of qualifying symptoms for swabbing was 
broader, and additionally included myalgia, chills, sore 
throat, headache, nasal congestion, diarrhoea, runny 
nose, fatigue, nausea, vomiting, and loss of appetite.
In all studies, if participants were tested outside of the 
trial, either in their workplace if a health-care worker or 
by private providers, these results were recorded and 
assessed by a masked independent endpoint review 
committee. The source of each swab was recorded plus 
the details of the test kit where available.
To test for asymptomatic infections, participants in 
COV002 in the UK were asked to provide a weekly self-
administered nose and throat swab for NAAT testing 
from 1 week after first vaccination using kits provided by 
the UK Department of Health and Social Care (DHSC). 
Participants were given home test kits provided by the 
DHSC that included step-by-step instructions on how 
to do a self-swab and a link to a demonstration video. 
The site trial team provided support with logistics of 
packaging and returning test kits and tracking swab 
results to participants if required. Swabs were taken by 
participants in their homes and posted to dedicated 
DHSC testing laboratories for processing. Participants 
were directly informed of their results by text or email 
from the National Health Service (NHS). Swab results 
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from participants in England and Wales were provided to 
the trial statistician on a daily basis by the NHS and 
matched to individuals based on personal identification 
data (name, date of birth, NHS number, and postcode). 
Swab results from participants in Scotland were 
unavailable to the study team at the time of the data 
cutoff for this analysis, but will be included in future 
analyses. Any swab results that were not able to be 
matched to a study participant using at least two pieces of 
personal data were not added to the study database.
In Brazil, there was no testing plan for asymptomatic 
infections. In South Africa, asymptomatic infections 
were detected from swabs obtained at study visits 
attended, but are not summarised here as there were 
only a small number of timepoints for detection of these 
cases.
All cases of COVID-19 were reviewed by two members 
of a masked independent clinical review team who 
assessed clinical details, including medical history, 
symptoms, adverse events, and swab results, and 
assigned severity scores according to the WHO clinical 
progression scale.8
For symptomatic participants in COV002 in the UK, 
weekly swabbing continued both before and after 
participants reported symptoms to the study site. Thus, a 
participant who reported symptoms and was clinically 
assessed might also have had additional swabs return 
positive results through the asymptomatic testing process 
for several weeks. In addition, due to the large number of 
health-care workers enrolled in these studies, some 
participants were tested according to their workplace 
testing policies and these results were also entered into 
the database for review by the masked endpoint evaluation 
committee. Further exploratory assessment of the length 
of time participants remained NAAT-positive, and the 
sources of information used for case detection will be 
done in future analyses.
Outcomes
The primary objective was to evaluate the efficacy of 
ChAdOx1 nCoV-19 vaccine against NAAT-confirmed 
COVID-19. The primary outcome was virologically 
confirmed, symptomatic COVID-19, defined as a NAAT-
positive swab combined with at least one qualifying 
symptom (fever ≥37·8°C, cough, shortness of breath, or 
anosmia or ageusia).
All participants were given an emergency 24-h telephone 
number to contact the on-call study physician for the 
duration of the study to report any illnesses. Serious 
adverse events were recorded throughout the study and 
reviewed at each study visit, with causality assigned by the 
site investigator. Events were clinically coded according to 
the Medical Dictionary for Regulatory Activities.
Statistical analysis
The plan for assessing efficacy and safety for the ChAdOx1 
nCoV-19 vaccine is based on global analyses using all 
available data from four studies with analysis pooled 
across the studies. A global statistical analysis plan for 
pooling study data was developed, after extensive advice 
from regulators, to prespecify the analyses that would 
contribute to the assessment of efficacy and this was 
signed off before any data analysis was conducted.
Randomised participants who received at least one 
dose in all studies are included in the safety analysis. 
However, each study had to meet prespecified criteria of 
having at least five cases eligible for inclusion in the 
primary outcome before a study was included in efficacy 
analyses. Neither COV001 or COV005 met these criteria 
and so are not included in the efficacy assessment for 
this interim analysis. It is expected that they will be 
included in efficacy assessments in future analyses 
once more cases have accrued. Additionally, only efficacy 
groups for COV002 (ie, groups 4, 6, 9, and 10) were 
included.
Vaccine efficacy was calculated as 1 – adjusted relative 
risk (ChAdOx1 nCoV-19 vs control groups) computed 
using a Poisson regression model with robust variance.9 
The model contained terms for study, treatment group, 
and age group (18–55, 56–69, and ≥70 years) at ran-
domisation. A reduced model that did not contain a term 
for age was used for models affected by convergence 
issues due to having few cases in the older age groups. 
The logarithm of the period at risk for the primary 
endpoint for pooled analysis was used as an offset 
variable in the model to adjust for volunteers having 
different follow-up times during which the events 
occurred. Cumulative incidence is presented using the 
Kaplan-Meier method.
The global pooled analysis plan allowed for an interim 
and a final efficacy analysis with α adjusted between 
the two analyses using a flexible gamma α-spending 
function, with significance being declared if the lower 
bound of the (1 − α)% CI is greater than 20%. Evidence of 
efficacy at the time of the interim analysis was not 
considered reason to stop the trials and all trials are 
continuing to accrue further data that will be included in 
future analyses.
The first interim analysis was planned to be triggered 
when at least 53 cases in participants who had received 
two standard-dose vaccines (SD/SD) had accrued that 
met the primary outcome definition more than 14 days 
after the second dose. This analysis provides 77% power 
for the 20% threshold to assume a true vaccine efficacy 
of 70%. Although the number of cases in the SD/SD 
cohort was used as the trigger for the interim analysis, 
the pre specified primary analysis included both SD/SD 
and LD/SD recipients. Due to the rapid increase in 
incidence of COVID-19 in the UK in October, more than 
53 cases had accrued by the time of data lock for this 
interim analysis. There were 98 cases available for 
inclusion in the SD/SD cohorts. Based on these numbers, 
the α level calculated using the gamma α-spending 
function for this analysis is 4·16%.
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Participants were excluded from the primary efficacy 
analysis if they were seropositive at baseline or had no 
baseline result. Other exclusions included those with 
NAAT-positive swabs within 14 days after the second 
vaccination, or those who discontinued from the study 
before having met the primary efficacy endpoint with a 
follow-up time of less than 15 days after the second 
vaccination. All reasons for exclusion are shown in 
appendix 1 (pp 5–8).
An analysis of efficacy after the first standard-dose 
vaccine in those who only received standard-dose vaccines 
was undertaken as a secondary analysis. Individuals were 
excluded if they had a NAAT-positive swab within 21 days 
after their first standard-dose vaccine.
Participants were analysed according to the vaccines 
they received. Sensitivity analyses included those who 
were seropositive at baseline and an intention-to-treat 
analysis. Safety analyses include all randomised partici-
pants who received at least one dose of any vaccine in any 
study.
Prespecified subgroup analyses are not included in this 
report but will be presented in future analyses when 
a larger dataset is available. However, in response to 
reviewer and editorial comments, a small number of 
exploratory subgroup comparisons has been included to 
explore differences in efficacy in the LD/SD and SD/SD 
groups and potential confounder variables. The LD/SD 
cohort in the UK comprised participants aged 18–55 years 
who received their second dose after a substantial gap. 
Age and the time difference between vaccines were 
therefore potential confounders and were explored 
further in subgroup analyses, restricted to those aged 
18–55 years, those with more than 8 weeks’ interval 
between vaccine doses, and a comparison of those in the 
SD/SD cohort receiving vaccines at short (<6 weeks) 
or long (≥6 weeks) intervals. Subgroup comparisons 
were done by incor porating the treatment-by-subgroup 
interaction term in the model and reporting the p value 
for the interaction term.
Data analysis was done using R (version 3.6.1 or later). 
Robust Poisson models were fitted using the PROC 
GENMOD function in SAS (version 9.4). The α level for 
the analysis was calculated using the gsDesign function 
in R. The cutoff date for inclusion in the analysis was 
Nov 4, 2020, and the data lock date was Nov 21, 2020.
The four trials are registered at ISRCTN89951424 
(COV003) and ClinicalTrials.gov, NCT04324606 (COV001), 
NCT04400838 (COV002), and NCT04444674 (COV005).
Role of the funding source
AstraZeneca reviewed the data from the study and the final 
manuscript before submission, but the academic authors 











MenACWY plus saline 
(n=2025)
Age, years
18–55 1367 (100·0%) 1374 (100·0%) 1879 (79·0%) 1922 (79·1%) 1843 (89·3%) 1833 (90·5%)
56–69 0 0 285 (12·0%) 293 (12·1%) 209 (10·1%) 187 (9·2%)
≥70 0 0 213 (9·0%) 215 (8·8%) 11 (0·5%) 5 (0·2%)
Sex
Female 886 (64·8%) 927 (67·5%) 1378 (58·0%) 1437 (59·1%) 1261 (61·1%) 1156 (57·1%)
Male 481 (35·2%) 447 (32·5%) 999 (42·0%) 993 (40·9%) 802 (38·9%) 869 (42·9%)
BMI, kg/m² 25·2 (22·8–28·7) 25·3 (22·7–28·8) 25·4 (22·9–28·7) 25·5 (22·9–29·1) 25·6 (22·8–29·1) 25·6 (23·1–29·0)
Ethnicity
White 1257 (92·0%) 1278 (93·0%) 2153 (90·6%) 2214 (91·1%) 1357 (65·8%) 1366 (67·5%)
Black 6 (0·4%) 2 (0·1%) 17 (0·7%) 14 (0·6%) 230 (11·1%) 210 (10·4%)
Asian 76 (5·6%) 59 (4·3%) 137 (5·8%) 138 (5·7%) 54 (2·6%) 53 (2·6%)
Mixed 19 (1·4%) 22 (1·6%) 48 (2·0%) 42 (1·7%) 410 (19·9%) 386 (19·1%)
Other 9 (0·7%) 13 (0·9%) 22 (0·9%) 22 (0·9%) 12 (0·6%) 10 (0·5%)
Health and social care 
setting workers
1236 (90·4%) 1253 (91·2%) 1441 (60·6%) 1513 (62·3%) 1833 (88·9%) 1775 (87·7%)
Comorbidities
Cardiovascular disease 104 (7·6%) 92 (6·7%) 264 (11·1%) 266 (10·9%) 271 (13·1%) 244 (12·0%)
Respiratory disease 158 (11·6%) 176 (12·8%) 285 (12·0%) 316 (13·0%) 215 (10·4%) 210 (10·4%)
Diabetes 18 (1·3%) 15 (1·1%) 58 (2·4%) 60 (2·5%) 59 (2·9%) 60 (3·0%)
Data are n (%) or median (IQR). The primary efficacy population (LD/SD and SD/SD) includes randomly assigned participants who were seronegative at baseline and received LD/SD or SD/SD or were in the 
corresponding control group, and remained on study more than 14 days after their second dose without having had a previous virologically confirmed severe acute respiratory syndrome coronavirus 2 infection. 
In addition, for groups in COV002, only efficacy groups (ie, groups 4, 6, 9, and 10) are included. LD/SD=low-dose prime plus standard-dose boost. SD/SD=two standard-dose vaccines given. 
MenACWY=meningococcal group A, C, W, and Y conjugate vaccine. BMI=body-mass index.
Table 1: Baseline characteristics of participants included in the primary efficacy population, by study and dosing strategy
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retained editorial control. All other funders of the study 
had no role in the study design, data collection, data 
analysis, data interpretation, or writing of the report. 
All authors had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between April 23 and Nov 4, 2020, 23 848 participants 
were recruited and vaccinated across the four studies: 
1077 in COV001 (UK), 10 673 in COV002 (UK), 10 002 in 
COV003 (Brazil), and 2096 in COV005 (South Africa). 
11 636 participants in COV002 and COV003 met the 
inclusion criteria for the primary analysis, 5807 of whom 
received two doses of ChAdOx1 nCoV-19 and 5829 of 
whom received two doses of control product. A trial 
profile and reasons for exclusion from the primary 
analysis are shown in appendix 1 (pp 5–7). Here, we 
provide safety data on 74 341 person-months of follow-up 
after first dose (median 3·4 months, IQR 1·3–4·8) and 
29 060 person-months of follow-up after two doses 
(median 2·0, 1·3–2·3).
Of the participants in COV002 and COV003 included 
in the primary efficacy analyses, the majority were 
aged 18–55 years (6542 [86·7%] of 7548 in the UK 
and 3676 [89·9%] of 4088 in Brazil; table 1). Those aged 
56 years or older were recruited later and contributed 
12·2% of the total cohort in the current analysis 
(1006 [13·3%] in the UK and 412 [10·1%] in Brazil). 
7045 (60·5%) participants were female. 6902 (91·4%) 
participants in the UK and 2723 (66·6%) participants in 
Brazil were white (table 1). Baseline participants of the 
safety population are shown in appendix 1 (pp 9–10).
The timing of priming and booster vaccine admin-
istration varied between studies. As protocol amendments 
to add a booster dose took place when the trials were 
underway, and owing to the time taken to manufacture 
and release a new batch of vaccine, doses could not 
be administered at a 4-week interval. 1459 (53·2%) of 
2741 participants in COV002 in the LD/SD group received 
a second dose at least 12 weeks after the first (median 
84 days, IQR 77—91) and only 22 (0·8%) received a second 
dose within 8 weeks of the first. The median interval 
between doses for the SD/SD group in COV002 was 
69 days (50–86). Conversely, the majority of participants 
in COV003 in the SD/SD group (2493 [61·0%] of 4088) 
received a second dose within 6 weeks of the first (median 




ChAdOx1 nCoV-19 Control Vaccine efficacy (CI*)








All LD/SD and SD/SD 
recipients
131 30/5807 (0·5%) 44·1 (248 299) 101/5829 (1·7%) 149·2 (247 228) 70·4% (54·8 to 80·6)†
COV002 (UK) 86 18/3744 (0·5%) 38·6 (170 369) 68/3804 (1·8%) 145·7 (170 448) 73·5% (55·5 to 84·2)
LD/SD recipients 33 3/1367 (0·2%) 14·9 (73 313) 30/1374 (2·2%) 150·2 (72 949) 90·0% (67·4 to 97·0)‡§
SD/SD recipients 53 15/2377 (0·6%) 56·4 (97 056) 38/2430 (1·6%) 142·4 (97 499) 60·3% (28·0 to 78·2)
COV003 (Brazil; all SD/SD) 45 12/2063 (0·6%) 56·2 (77 930) 33/2025 (1·6%) 157·0 (76 780) 64·2% (30·7 to 81·5)‡




18 7/5807 (0·1%) 10·3 (248 299) 11/5829 (0·2%) 16·3 (247 228) 36·4% (−63·8 to 75·3)‡
Any symptomatic COVID-19 
disease
149 37/5807 (0·6%) 54·4 (248 299) 112/5829 (1·9%) 165·5 (247 228) 67·1% (52·3 to 77·3)
Asymptomatic or symptoms 
unknown (COV002)
69 29/3288 (0·9%) 69·8 (151 673) 40/3350 (1·2%) 96·0 (152 138) 27·3% (−17·2 to 54·9)
LD/SD recipients 24 7/1120 (0·6%) 41·4 (61 782) 17/1127 (1·5%) 100·6 (61 730) 58·9% (1·0 to 82·9)‡
SD/SD recipients 45 22/2168 (1·0%) 89·4 (89 891) 23/2223 (1·0%) 92·9 (90 408) 3·8% (−72·4 to 46·3)
Any NAAT-positive swab 221 68/5807 (1·2%) 100·0 (248 299) 153/5829 (2·6%) 226·0 (247 228) 55·7% (41·1 to 66·7)
Vaccine efficacy was calculated from the robust Poisson model. The primary efficacy population (LD/SD and SD/SD) includes randomly assigned participants who were 
seronegative at baseline and received LD/SD or SD/SD or were in a corresponding control group, and remained on study more than 14 days after their second dose without 
having had a previous virologically confirmed SARS-CoV-2 infection. In addition, for groups in COV002, only efficacy groups (ie, groups 4, 6, 9, and 10) are included. 
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. LD/SD=low-dose prime plus standard-dose boost. SD/SD=two standard-dose vaccines given. NAAT=nucleic acid 
amplification test. *CIs are 95% unless indicated otherwise. †95·8% CI used for primary analysis. ‡Vaccine efficacy calculated from a reduced robust Poisson model that was not 
adjusted for age. All other models included an adjustment for age. §p value for interaction term comparing LD/SD with SD/SD is p=0·010. ¶Other non-primary symptomatic 
COVID-19 disease includes cases who have symptoms other than the five main symptoms that are required for inclusion in the primary analysis (eg, a participant who has 
diarrhoea and malaise but no fever, cough, shortness of breath, anosmia, or ageusia).
Table 2: Efficacy against SARS-CoV-2 more than 14 days after a second dose of ChAdOx1 nCoV-19 vaccine in the primary efficacy population
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A small proportion of participants were seropositive 
at baseline (138 [1·3%] of 10 673 in the UK and 235 [2·3%] 
of 10 002 in Brazil). Three participants seropositive at 
baseline had subse quent NAAT-positive swabs. One par-
ticipant had an asymptomatic infection 3 weeks after a 
first dose of ChAdOx1 nCoV-19. Two other participants in 
the control group had symptomatic infections 8 weeks 
and 21 weeks after their baseline sample was taken.
There were 131 cases of symptomatic COVID-19 in 
LD/SD or SD/SD recipients who were eligible for 
inclusion in the primary efficacy analysis more than 
14 days after the second dose of vaccine (table 2). There 
were 30 (0·5%) cases among 5807 participants in the 
vaccine arm and 101 (1·7%) cases among 5829 par-
ticipants in the control group, resulting in vaccine 
efficacy of 70·4% (95·8% CI 54·8–80·6; table 2; figure). 
In participants who received two standard-dose vaccines, 
vaccine efficacy was 62·1% (95% CI 41·0–75·7), whereas 
in those who received a low dose as their first dose of 
vaccine, efficacy was higher at 90·0% (67·4–97·0; 
pinteraction=0·010; table 2; appendix 1 pp 12–13).
In England and Wales, 129 529 weekly self-swabs 
were processed by the DHSC, of which 126 324 (97·5%) 
were matched to study participants. There were 
435 positive swabs, of which 354 (81·4%) were matched. 
Symptoms in these participants were not routinely 
assessed as swabs were done at home and sent for testing 
through the post. Asymptomatic infections or those with 
unreported symptoms were detected in 69 participants 
(table 2). Vaccine efficacy in the 24 LD/SD recipients was 
58·9% (95% CI 1·0 to 82·9), whereas it was 3·8% 
(−72·4 to 46·3) in the 45 participants receiving SD/SD 
(table 2).
Results from sensitivity analyses, including partici-
pants who were seropositive at baseline and by intention 
to treat, were very similar to main results (data not 
shown).
Results from the subgroup comparisons presented in 
this analysis were similar to overall results (table 3). In 
the SD/SD UK cohort who were aged 18–55 years, 
49 cases were available for inclusion in the analysis 
and vaccine efficacy was 59·3% (95% CI 25·1 to 77·9; 
pinteraction=0·019; table 3). When further restricted to those 
who received their vaccines more than 8 weeks apart, 
33 cases were included in the SD/SD analysis and 
vaccine efficacy was 65·6% (24·5 to 84·4; pinteraction=0·082; 
table 3; appendix 1 pp 12–13). In the SD/SD cohorts in 
the UK and Brazil, vaccine efficacy was similar when 
analysed in subgroups according to time between 
Figure: Kaplan-Meier cumulative incidence of primary symptomatic, NAAT-positive COVID-19
Cumulative incidence of symptomatic COVID-19 after two doses (left) or after first standard dose in participants 
receiving only standard-dose vaccines (right). Grey shaded areas show the exclusion period after each dose in 
which cases were excluded from the analysis. Blue and red shaded areas show 95% CIs. LD/SD=low-dose prime plus 
standard-dose boost. MenACWY=meningococcal group A, C, W, and Y conjugate vaccine. NAAT=nucleic acid 


















































































































ChAdOx1 nCoV-19 Control Vaccine efficacy (95% CI) p value for 
interaction
COV002 (UK), age 18–55 years* ·· ·· ·· ·· 0·019
LD/SD recipients 33 3/1367 (0·2%) 30/1374 (2·2%) 90·0% (67·3 to 97·0) ··
SD/SD recipients 49 14/1879 (0·7%) 35/1922 (1·8%) 59·3% (25·1 to 77·9) ··
COV002 (UK), age 18–55 years with >8 weeks’ 
interval between vaccine doses*
·· ·· ·· ·· 0·082
LD/SD recipients 33 3/1357 (0·2%) 30/1362 (2·2%) 90·0% (67·3 to 97·0) ··
SD/SD recipients 34 8/1407 (0·6%) 26/1512 (1·7%) 65·6% (24·5 to 84·4) ··
All SD/SD (UK and Brazil)† ·· ·· ·· ·· 0·557
<6 weeks’ interval between vaccine doses 28 9/1702 (0·5%) 19/1698 (1·1%) 53·4% (−2·5 to 78·8) ··
≥6 weeks’ interval between vaccine doses 70 18/2738 (0·7%) 52/2757 (1·9%) 65·4% (41·1 to 79·6) ··
Cohorts are all subsets of the primary efficacy population. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. LD/SD=low-dose prime plus standard-dose boost. 
SD/SD=two standard-dose vaccines given. BMI=body-mass index. *Models adjusted for BMI (<30 vs ≥30 kg/m²), health-care worker status (yes vs no), and ethnicity 
(white vs non-white). †Model adjusted for BMI (<30 vs ≥30 kg/m²), health-care worker status (yes vs no), ethnicity (white vs non-white), age (<56 years vs ≥56 years), and study 
(COV002 vs COV003).
Table 3: Subgroup comparisons of efficacy against SARS-CoV-2 more than 14 days after a second dose of ChAdOx1 nCoV-19 vaccine in the primary 
efficacy population
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vaccines, at 53·4% (−2·5 to 78·8) in participants 
with less than 6 weeks’ interval between doses and 
65·4% (41·1 to 79·6) in participants with at least 6 weeks’ 
interval (pinteraction=0·56; table 3).
For our secondary analysis of cases occurring more 
than 21 days after the first standard dose in partici-
pants who received only standard doses, there were 
192 included cases with a vaccine efficacy of 64·1% 
(95% CI 50·5–73·9; table 4; figure)
More than 21 days after their first dose, ten participants 
were hospitalised due to COVID-19 (defined as WHO 
clinical progression score ≥4), two of whom were 
assessed as having severe COVID-19 (WHO score ≥6), 
including one fatal case. All ten cases were in the control 
group (table 5).
Five cases included in the primary analysis occurred in 
those participants older than 55 years of age. Vaccine 
efficacy in older age groups could not be assessed but will 
be determined, if sufficient data are available, in a future 
analysis after more cases have accrued.
Across all four studies, the vaccine had a good safety 
profile with serious adverse events and adverse events of 
special interest balanced across the study arms. Serious 
adverse events occurred in 168 participants, 79 of whom 
received ChAdOx1 nCoV-19 and 89 of whom received 
MenACWY or saline control (appendix 1 pp 15–18). 
There were 175 events (84 in the ChAdOx1 nCoV-19 
group and 91 in the control group), three of which were 
considered possibly related to either the experimental or 
a control vaccine. A case of haemolytic anaemia in the 
control group in the UK phase 1/2 study occurring 
10 days after MenACWY vaccine was considered possibly 
related to the intervention and has been previously 
described.5 A case of transverse myelitis was reported 
14 days after ChAdOx1 nCoV-19 booster vac cination 
as being possibly related to vaccination, with the 
independent neurological committee considering the 
most likely diagnosis to be of an idiopathic, short 
segment, spinal cord demyelination. A potentially 
vaccine-related serious adverse event was reported 2 days 
after vaccination in South Africa in an individual who 
recorded fever higher than 40°C, but who recovered 
Total number 
of cases
ChAdOx1 nCoV-19 Control Vaccine efficacy (95% CI)
n/N (%) Incidence per 
1000 person-years 
(person-days of follow-up)
n/N (%) Incidence per 
1000 person-years 
(person-days of follow-up)
COV002 (UK) 90 28/3060 (0·9%) 35·4 (288 955) 62/3064 (2·0%) 78·5 (288 395) 55·0% (29·7 to 71·1)
COV003 (Brazil) 102 23/3247 (0·7%) 46·7 (179 743) 79/3233 (2·4%) 162·4 (177 693) 71·2% (54·2 to 81·9)
Primary symptomatic COVID-19* 192 51/6307 (0·8%) 39·7 (468 698) 141/6297 (2·2%) 110·5 (466 088) 64·1% (50·5 to 73·9)
Other non-primary symptomatic 
COVID-19†
21 12/6307 (0·2%) 9·4 (468 698) 9/6297 (0·1%) 7·1 (466 088) −32·8% (−214·8 to 44·0)‡
Any symptomatic COVID-19 213 63/6307 (1·0%) 49·1 (468 698) 150/6297 (2·4%) 117·5 (466 088) 58·3% (44·0 to 68·9)
Asymptomatic or symptoms unknown 
(COV002)
71 34/2751 (1·2%) 46·8 (265 142) 37/2760 (1·3%) 51·0 (264 994) 7·8% (−46·7 to 42·1)
Any NAAT-positive swab 291 102/6307 (1·6%) 79·5 (468 698) 189/6297 (3·0%) 148·1 (466 088) 46·3% (31·8 to 57·8)
Vaccine efficacy was calculated from the robust Poisson model. The first-standard-dose efficacy population includes participants seronegative at baseline who received only standard dose vaccines or were in the 
corresponding control group, and remained on study 22 days after their first dose without having had a previous virologically confirmed SARS-CoV-2 infection. In addition, for groups in COV002, only efficacy 
groups (ie, groups 4, 6, 9, and 10) are included. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. NAAT=nucleic acid amplification test. *NAAT-positive swab plus at least one of cough, shortness of 
breath, fever higher than 37·8°C, anosmia, or ageusia. †Other non-primary symptomatic COVID-19 disease includes cases that have symptoms other than the five main symptoms required for inclusion in the 
primary analysis (eg, a participant who has diarrhoea and malaise but no fever, cough, shortness of breath, anosmia, or ageusia). ‡Vaccine efficacy was calculated from a reduced robust Poisson model (excluding 
the age group category due to the full model failing to converge). Participants with a low-dose prime were excluded.








Hospitalisation (WHO clinical progression score ≥4)
≤21 days after the first dose 2* 6
>21 days after the first dose and ≤14 days 
after the second dose
0 5
>14 days after the second dose 0 5
Severe COVID-19 (WHO clinical progression score ≥6)
≤21 days after the first dose 0 0
>21 days after the first dose and ≤14 days 
after the second dose
0 1
>14 days after the second dose 0 1
The safety population includes all randomisation participants who received at 
least one dose of vaccine. Severe COVID-19 (WHO score ≥6) is a subset of 
hospitalisations (WHO score ≥4). Cases were eligible for inclusion in efficacy if the 
first symptom or first NAAT-positive result was on or before the data cutoff date 
(Nov 4, 2020). Two cases appear in this table that do not appear in the table for 
serious adverse events in appendix 1 (pp 15–20) as the adverse event reporting 
date was after the data cutoff date. MenACWY=meningococcal group A, C, W, 
and Y conjugate vaccine. NAAT=nucleic acid amplification test. *One case on the 
day of the first vaccination and one case 10 days after the first dose.
Table 5: Hospitalisation for COVID-19 and severe COVID-19 in the safety 
population
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rapidly without an alternative diagnosis and was not 
admitted to hospital. The participant remains masked to 
group allocation, continues in the trial, and received a 
second dose of the allocated vaccine without a similar 
reaction.
There were two additional cases of transverse myelitis 
that were originally reported as potentially related but 
later determined to be unlikely to be related to vaccination 
by an independent committee of neurological experts. 
One case that occurred 10 days after a first vaccination 
with ChAdOx1 nCoV-19 was initially assessed as possibly 
related, but later considered unlikely to be related by the 
site investigator when further investigation revealed pre-
existing, but previously unrecognised, multiple sclerosis. 
The second case was reported 68 days after MenACWY 
vaccination. While considered possibly related by the site 
investigator at the time of reporting, an independent 
panel of neurological experts considered this to be 
unlikely. All trial participants have recovered, or are in a 
stable or improving condition.
There were four non-COVID-19 deaths reported across 
the studies (three in the control arm and one in the 
ChAdOx1 nCoV-19 arm) that were all considered 
unrelated to the vaccine, with cause of death assessed as 
road traffic accident, blunt force trauma, homicide, and 
fungal pneumonia.
Discussion
Here, we present the first interim safety and efficacy 
data for a viral vector coronavirus vaccine, ChAdOx1 
nCoV-19, evaluated in four trials across three continents, 
showing significant vaccine efficacy of 70·4% after 
two doses and protection of 64·1% after at least one 
standard dose, against symptomatic disease, with no 
safety concerns.
The prespecified analysis population, which was 
determined following feedback from national and 
international regulators before unblinding of the study, 
included a pooled analysis from several countries to 
improve generalisability, and inclusion of two dose 
subgroups within the UK trial. This pooling strategy was 
authorised by the chief investigator (AJP) and study 
statistician (MV), with no concerns about pooling 
different control groups, and was accepted by regulators 
involved in the discussions. There had been initial 
concern that the LD/SD regimen might have lower 
efficacy than SD/SD, and the regulatory authority 
acceptance of the inclusion of the two trial regimens 
(LD/SD and SD/SD) in analysis was based on the 
observation that these regimens generated similar levels 
of binding antibody, and would therefore increase the 
sample size available for analysis without compromising 
efficacy. The discussion about pooling and inclusion of 
LD/SD was made at a time when disease rates were low 
in the UK and, in the face of the pandemic, it was agreed 
that pooling could provide the earliest possible read on 
efficacy that could contribute to public health.
No previous trials have been published on the efficacy 
of a viral-vectored coronavirus vaccine and so this study 
provides the first peer-reviewed evidence that induction 
of immune responses against spike protein using viral 
vectors provides protection against the disease in 
humans, as has been seen in animal models.
In participants who received two standard doses, 
efficacy against primary symptomatic COVID-19 was 
consistent in both the UK (60·3% efficacy) and Brazil 
(64·2% efficacy), indicating these results are generalisable 
across two diverse settings with different timings for the 
booster dose (with most participants in the UK receiving 
the booster dose more than 12 weeks after the first dose 
and most participants in Brazil receiving their second 
dose within 6 weeks of the first). Exploratory subgroup 
analyses included at the request of reviewers and editors 
also showed no significant difference in efficacy esti-
mates when com paring those with a short time 
window between doses (<6 weeks) and those with longer 
(≥6 weeks), although further detailed exploration of the 
timing of doses might be warranted.
Efficacy of 90·0% seen in those who received a low 
dose as prime in the UK was intriguingly high compared 
with the other findings in the study. Although there is 
a possibility that chance might play a part in such 
divergent results, a similar contrast in efficacy between 
the LD/SD and SD/SD recipients with asymptomatic 
infections provides support for the observation (58·9% 
[95% CI 1·0 to 82·9] vs 3·8% [−72·4 to 46·3]). Explora-
tory sub group analyses, included at the request of 
reviewers and editors, that were restricted to participants 
aged 18–55 years, or aligned (>8 weeks) intervals 
between doses, showed similar findings. Use of a low 
dose for priming could provide substantially more 
vaccine for distribution at a time of constrained supply, 
and these data imply that this would not compromise 
protection. While a vaccine that could prevent COVID-19 
would have a substantial public health benefit, pre-
vention of asymptomatic infection could reduce viral 
transmission and protect those with underlying health 
conditions who do not respond to vaccination, those 
who cannot be vaccinated for health reasons, and those 
who will not or cannot access a vaccine, providing wider 
benefit for society. However, the wide CIs around our 
estimates show that further data are needed to confirm 
these preliminary findings, which will be done in future 
analyses of the data accruing in these ongoing trials.
Similar results have been seen for other vaccines where 
a reduced number or type of priming dose in infancy can 
lead to higher responses to a booster vaccine.10 Further 
work is needed to determine the mechanism of the 
increased efficacy with a LD/SD regimen, which might 
be due to higher levels of neutralising antibody, lower 
levels of anti-vector immunity with lower vector-derived 
antigen content of the first dose, or differential antibody 
functionality or cellular immunity, including altered 
avidity or immunodominance.
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Other coronavirus vaccine developers have released 
preliminary high-level results in public statements, 
including more than 90% efficacy reported for the lipid 
nanoparticle mRNA vaccine BNT162b2,11 92% efficacy 
for the Sputnik V vaccine (developed at the National 
Research Centre for Epidemiology and Microbiology),12 
and 94·5% for the Moderna lipid nanoparticle 
mRNA-1273 vaccine.13 The possibility that more than one 
efficacious vaccine against COVID-19 might be approved 
for use in the near future is encouraging. However, 
control of pandemic coronavirus will only be achieved if 
the licensure, manufacturing, and distribution of these 
vaccines can be achieved at an unprecedented scale and 
vaccination is rolled out to all those who are vulnerable.
The US Food and Drug Administration’s guidelines 
indicate that they would license a vaccine against the 
pandemic virus that showed at least 50% efficacy14 and 
WHO have indicated a minimum efficacy of 50% in its 
target product profile.15 A modelling study found that a 
vaccine with efficacy of 60–80% could allow reduction in 
physical distancing measures, but this would still require 
high coverage.16 The findings here indicate that the 
efficacy of ChAdOx1 nCoV-19 exceeds these thresholds 
and has the potential to have a public health impact.
Much consideration has been given to the statistical 
confidence in vaccine efficacy estimates, given the size 
of the global population who might be vaccinated. To 
ensure that point estimates of efficacy in clinical trials 
are sufficiently robust, some regulatory authorities 
consider that the lower bound of the CI for efficacy 
should be higher than 20% (personal communication), 
with other authorities more stringent and anticipating a 
lower bound of 30% for licensure.14 Here, we present data 
that exceed both these thresholds in the pooled analysis, 
which we had agreed with regulators before unblinding 
of the study, and also meet the thresholds set in the 
individual analyses of trials by country and by study arm.
We designed our studies early in the pandemic and 
fixed our primary symptomatic disease endpoint on the 
basis of expert analysis and guidelines from Public 
Health England and WHO as the first wave of disease 
spread around the world, although these have now been 
substantially updated.17,18 We have used a restricted 
definition of symptomatic disease, since many other 
symptoms that are associated with COVID-19 disease are 
non-specific. Since endpoints in protocols for different 
vaccines are not well aligned, we recognise that it will 
be difficult to compare efficacy across programmes. 
However, we have also included hospital admissions and 
severe disease as an endpoint in the current study, which 
might be easier to assess in comparison with other 
vaccines, and found that in the ten cases available 
for analysis more than 21 days after the first dose, there 
was complete protection against hospitali sation for 
COVID-19.
While the data presented here show that ChAdOx1 
nCov-19 is efficacious against symptomatic disease, with 
most cases accruing in adults younger than 55 years of age 
so far, an important public health consideration is the 
morbidity and mortality of the disease in an older adult 
population and thus the potential efficacy in this age 
group. We have reported immunogenicity data showing 
similar immune responses following vaccination with two 
doses of ChAdOx1 nCov-19 in older adults, including those 
older than 70 years of age, when compared with those 
younger than 55 years.6 As older age groups were recruited 
later than younger age groups, there has been less time for 
cases to accrue and as a result, efficacy data in these cohorts 
are currently limited by the small number of cases, but 
additional data will be available in future analyses.
These trials, conducted on three different continents, 
enrolled geographically and ethnically diverse popula-
tions. Severe COVID-19 has been seen to dispropor-
tionately affect people of non-white ethnicity, as well as 
those who are male, overweight, and the elderly.19,20
In our studies, the demographic characteristics of those 
enrolled varied between countries. In the UK, the enrolled 
population was predominantly white and, in younger age 
groups, included more female participants due to the 
focus on enrolment of health-care workers. This is a 
typically lower risk population for severe COVID-19. The 
demographic profile combined with the weekly self-
swabbing for asymptomatic infection in the UK results in 
a milder case-severity profile. In Brazil, there was a larger 
proportion of non-white ethnicities, and again the majority 
of those enrolled were health-care workers.
We have previously reported on the local and systemic 
reactogenicity of ChAdOx1 nCoV-19 and shown that it 
is tolerated and that the side-effects are less both in 
intensity and number in older adults, with lower doses, 
and after the second dose. Although there were many 
serious adverse events reported in the study in view of 
the size and health status of the population included, 
there was no pattern of these events that provided a safety 
signal in the study. Three cases of transverse myelitis 
were initially reported as suspected unexpected serious 
adverse reactions, with two in the ChAdOx1 nCoV-19 
vaccine study arm, triggering a study pause for careful 
review in each case. Independent clinical review of these 
cases has indicated that one in the experimental group 
and one in the control group are unlikely to be related to 
study interventions, but a relationship remained possible 
in the third case. Careful monitoring of safety, including 
neurological events, continues in the trials. All safety 
data will be provided to regulators for review.
In this interim analysis, we have not been able to 
assess duration of protection, since the first trials were 
initiated in April, 2020, such that all disease episodes 
have accrued within 6 months of the first dose being 
administered. Further evidence will be required to 
determine duration of protection and the need for 
additional booster doses of vaccine.
The results presented in this Article constitute the key 
findings from the first interim analysis, which are 
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provided for rapid review by the public and policy makers. 
In future analyses with additional data included as they 
accrue, we will investigate differences in key subgroups 
such as older cohorts, ethnicity, dose regimen, and timing 
of booster vaccines, and we will search for correlates of 
protection.
Until widespread immunity halts the spread of 
SARS-CoV-2, physical distancing measures and novel 
therapies are needed to control COVID-19. In the 
meantime, an efficacious vaccine has the potential to 
have a major impact on the pandemic if used in 
populations at risk of severe disease. Here, we have 
shown for the first time that a viral vector vaccine, 
ChAdOx1 nCoV-19, is efficacious and could contribute to 
control of the disease in this pandemic.
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